
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About


Fractyl Health, Inc. Common Stock (GUTS)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: GUTS (2-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $6.67
1 Year Target Price $6.67
3 | Strong Buy |
1 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 6.75% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 70.20M USD | Price to earnings Ratio - | 1Y Target Price 6.67 |
Price to earnings Ratio - | 1Y Target Price 6.67 | ||
Volume (30-day avg) 4 | Beta - | 52 Weeks Range 0.82 - 3.67 | Updated Date 08/28/2025 |
52 Weeks Range 0.82 - 3.67 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.1 |
Earnings Date
Report Date 2025-08-12 | When - | Estimate -0.43 | Actual -0.545 |
Profitability
Profit Margin - | Operating Margin (TTM) -587305.86% |
Management Effectiveness
Return on Assets (TTM) -59.87% | Return on Equity (TTM) -379.75% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 109627935 | Price to Sales(TTM) 4129.47 |
Enterprise Value 109627935 | Price to Sales(TTM) 4129.47 | ||
Enterprise Value to Revenue 6448.7 | Enterprise Value to EBITDA - | Shares Outstanding 70881400 | Shares Floating 27939068 |
Shares Outstanding 70881400 | Shares Floating 27939068 | ||
Percent Insiders 3.34 | Percent Institutions 53.76 |
Upturn AI SWOT
Fractyl Health, Inc. Common Stock

Company Overview
History and Background
Fractyl Health is a medical technology company dedicated to developing novel, less invasive therapies for metabolic diseases, including type 2 diabetes and obesity. They were founded in 2010 with the goal of addressing the root causes of these conditions.
Core Business Areas
- Revita DMR System: The Revita DMR System is Fractyl Health's primary product. It is a minimally invasive endoscopic procedure designed to remodel the duodenal lining to improve glucose control and reduce insulin resistance in patients with type 2 diabetes.
- Preclinical Research: Fractyl Health continues to engage in preclinical research and development of new technologies and therapies related to metabolic disease.
Leadership and Structure
Fractyl Health is led by a team of experienced medical device and biotechnology executives. Details on specific individuals and the complete organizational structure would require access to the company's investor relations materials and recent filings with the SEC. The company operates with standard biotech structure, and is lead by a Chief Executive Officer and department heads.
Top Products and Market Share
Key Offerings
- Revita DMR System: The Revita DMR System is a minimally invasive endoscopic procedure that targets the duodenum. It is designed to regenerate the lining of the small intestine, aiming to improve insulin sensitivity and glucose control. Market share data specific to Revita DMR is difficult to obtain, as it is a relatively new and emerging technology. Revenue data requires private access. Competitors are largely other interventions for diabetes and obesity (medications, bariatric surgery).
Market Dynamics
Industry Overview
The market for diabetes and obesity treatments is large and growing, driven by the increasing prevalence of these conditions worldwide. The industry includes pharmaceutical companies, medical device manufacturers, and healthcare providers.
Positioning
Fractyl Health is positioned as an innovator in the treatment of type 2 diabetes and obesity, focusing on less invasive, durable therapies. Their competitive advantage lies in their unique approach to targeting the root causes of metabolic disease in the duodenum.
Total Addressable Market (TAM)
The TAM for type 2 diabetes and obesity treatments is estimated to be hundreds of billions of dollars globally. Fractyl Health is positioned to capture a portion of this market by providing a novel therapeutic option. A specific dollar amount would require further analysis of analyst reports.
Upturn SWOT Analysis
Strengths
- Novel technology platform (Revita DMR)
- Potential for durable glycemic control
- Minimally invasive procedure
- Strong intellectual property portfolio
Weaknesses
- Limited clinical data compared to established therapies
- Relatively new technology with an unproven long-term track record
- Dependence on key personnel
- Requires specialized training for physicians
Opportunities
- Expansion of clinical indications
- Partnerships with pharmaceutical companies and healthcare providers
- Geographic expansion to new markets
- Further development of technology platform
Threats
- Competition from established diabetes and obesity treatments (medications, surgery)
- Regulatory hurdles and reimbursement challenges
- Adverse events associated with Revita DMR
- Failure to demonstrate long-term efficacy
Competitors and Market Share
Key Competitors
- Novo Nordisk (NVO)
- Eli Lilly and Company (LLY)
- Medtronic (MDT)
Competitive Landscape
Fractyl Health faces significant competition from established pharmaceutical and medical device companies. Its success depends on demonstrating the safety, efficacy, and durability of Revita DMR compared to existing treatments.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is difficult to ascertain as a private company, but has likely focused on clinical trials and FDA approvals.
Future Projections: Future projections require access to company guidance or analyst models, which are not publicly available.
Recent Initiatives: Recent initiatives would center around continued clinical trials of Revita DMR and regulatory submissions.
Summary
Fractyl Health is an innovative private company working in the metabolic disease space. Their unique Revita DMR system offers promise, but faces hurdles of clinical validation, regulatory approval and commercial adoption. They compete in a market dominated by large players, making partnerships critical. Long-term success depends on positive clinical outcomes and strategic execution.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Press Releases
- Analyst Reports (Limited Access)
- SEC Filings of Competitors
Disclaimers:
This analysis is based on publicly available information and limited data. Financial data is estimated. Market share data is approximate and based on available industry reports and competitor filings. This is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Fractyl Health, Inc. Common Stock
Exchange NASDAQ | Headquaters Burlington, MA, United States | ||
IPO Launch date 2024-02-02 | Co-Founder, CEO & Director Dr. Harith Rajagopalan M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 103 | Website https://fractyl.com |
Full time employees 103 | Website https://fractyl.com |
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.